1 January 2020 in Neuroscience Letters
1 December 2013 in Pain Medicine
Background. ABCB1 is a major determinant of opioid bioavailability; however, no previous studies have provided positive evidence of an association betw
1 January 2021 in Neuroscience Letters
1 January 2010 in Journal of Smooth Muscle Research
Objective: To measure the effects of estrogen, progesterone and polypropylene mesh on vaginal smooth muscle cell proliferation. Methods: Primary smooth muscle cell (SMC) cultures were performed from vaginal biopsies which were then incubated with estradiol (0.1 μM, 1 μM, 10 μM), progesterone (5 nM, 50 nM, 0.5 μM), or polypropylene mesh to assess cell proliferation. Results: In vitro vaginal SMC proliferation was significantly increased by estradiol but not by progesterone or by polypropylene mesh (relative cell number, mean ± SD, control vs. estrogen 0.24 ± 0.02 vs. 0.28 ± 0.02, P=0.01; control vs. progesterone 0.24 ± 0.02 vs. 0.23 ± 0.02, P=NS and control vs. mesh, 0.24 ± 0.02 vs. 0.24 ± 0.01, P=NS). In addition, estradiol increased cell proliferation in a dose responsive fashion (estradiol dose: 0.1 μM, 1 μM, 10 μM) compared to control (P=0.01). Conclusion: Vaginal SMC proliferation is significantly increased by estrogen.
29 August 2022 in Evidence-Based Complementary and Alternative Medicine
JAJeimy Alfonso-Rodriguez
Purpose. This study aimed to investigate the analgesic effect and mechanism of electroacupuncture (EA) in nicotine withdrawal-induced hyperalgesia rats. Methods. Behavioral testing was conducted twice a week for 7 weeks during nicotine administration using von Frey filaments. Electroacupuncture at the bilateral Zusanli and Taichong points was applied daily for 3 days during nicotine withdrawal. Western blot analysis and immunohistology were used to determine expression levels of pain-related factors in the spinal cord and midbrain periaqueductal gray (PAG). Results. Behavioral tests showed that electroacupuncture had a significant analgesic effect on nicotine withdrawal-induced hyperalgesic rats. Western blot results demonstrated that, in hyperalgesic rats, the expressions of nicotinic acetylcholine receptors (subunits: nAChR α7, α4, or β2) decreased in the spinal cord, nAChR α7, and β2 decreased in PAG. The proinflammatory factor cyclooxygenase 2 (COX2) and the activated microglia (ionized calcium-binding adaptor molecule 1, Iba1 positive cells) increased in the spinal cord and PAG compared to controls. After electroacupuncture treatment, nAChR α7 and nAChR β2 expressions increased significantly, and COX2 and Iba1 expressions decreased in the spinal cord. Compared with the nonelectroacupuncture nicotine withdrawal group, electroacupuncture stimulation increased the expression of nAChR α7 and nAChR α4 in the PAG of rats with electroacupuncture. Immunohistochemical results confirmed that electroacupuncture reversed nicotine withdrawal-induced changes in nAChR α7 positive neurons and Iba1-positive microglia in the dorsal horn of the spinal cord. Conclusion. Electroacupuncture treatment has an analgesic effect on nicotine withdrawal-induced pain in nicotine-dependent rats. The mechanism of analgesia of the electroacupuncture treatment relates to the increased expression of nAChR α7 and nAChR β2 proteins in the spinal cord, nAChR α7 in the PAG, and decreased expression of Iba1 and COX2 protein in the spinal cord.
1 October 2000 in Annals of Pharmacotherapy
OBJECTIVE: To screen 82 commonly used parenteral medications for compatibility with a new chlorhexidine-bearing central venous catheter, the ARROWg+ard Blue Plus. Evaluations were performed for completeness of drug delivery and impact, if any, of the drugs on the amount of chlorhexidine removed from the internal lumens. DESIGN: Drug solutions were prepared in dextrose 5% injection or NaCl 0.9% at common concentrations. Three 10-mL aliquots of each drug solution were delivered over 10 minutes, one aliquot through each lumen of the triple-lumen catheter. The initial drug concentrations of the admixtures and the effluent samples were analyzed by HPLC for chlorhexidine content and for the amount of drug delivered relative to its initial concentration. RESULTS: The delivery of the infusion solutions alone through sample catheters resulted in no more than trace amounts of chlorhexidine in the solution. Background amounts ranged from <2.5 to 6.1 μg/mL in the first 10 mL of solution. Administration of none of the drugs tested resulted in a substantial increase in chlorhexidine delivery. Furthermore, delivery of most of the drugs was at least 95% and usually was in excess of 97% of the initial concentration. Concentrations of five drugs, amikacin sulfate, cefoperazone sodium, cefotaxime sodium, cefepime HCl, and netilmicin sulfate were somewhat lower than the initial concentration (range 91–95%), but were still considered acceptable. CONCLUSIONS: The ARROWg+ard Blue Plus central venous catheter can be recommended for use with all of the 82 parenteral drugs tested.